Control system and process for application of energy to airway walls and other mediums

Information

  • Patent Grant
  • 7837679
  • Patent Number
    7,837,679
  • Date Filed
    Monday, July 17, 2006
    17 years ago
  • Date Issued
    Tuesday, November 23, 2010
    13 years ago
Abstract
The present invention includes a system for delivering energy to an airway wall of a lung comprising an energy delivering apparatus and a PID controller having one or more variable gain factors which are rest after energy deliver has begun. The energy delivering apparatus may include a flexible elongated member and a distal expandable basket having at least one electrode for transferring energy to the airway wall and at least one temperature sensor for measuring temperature. The PID controller determines a new power set point base on an error between a preset temperature and the measured temperature. The algorithm can be Pi+1=Pi+G(αei+βei−1+γei−2) where α, β and γ are preset values and α is from 1 to 2; β is from −1 to −2; and γ is from −0.5 to 0-5. In another variation, the controller is configured to shut down if various measured parameters are exceeded such as, for example, energy, impedance, temperature, temperature differences, activation time and combinations thereof. Methods for treating a target medium using a PID algorithm are also provided.
Description
FIELD OF THE INVENTION

This invention is related to systems for applying energy to lung airways and in particular, to a system and method for controlling the energy delivered to the airways using a PID algorithm to minimize error between a preset temperature and a measured temperature.


BACKGROUND

Various obstructive airway diseases have some reversible component. Examples include COPD and asthma. There are an estimated 10 million Americans afflicted with Asthma. Asthma is a disease in which bronchoconstriction, excessive mucus production, and inflammation and swelling of airways occur, causing widespread but variable airflow obstruction thereby making it difficult for the asthma sufferer to breathe. Asthma is a chronic disorder, primarily characterized by persistent airway inflammation. Asthma is further characterized by acute episodes of additional airway narrowing via contraction of hyper-responsive airway smooth muscle.


Reversible aspects of obstructive pulmonary disease generally include excessive mucus production in the bronchial tree. Usually, there is a general increase in bulk (hypertrophy) of the large bronchi and chronic inflammatory changes in the small airways. Excessive amounts of mucus are found in the airways and semisolid plugs of mucus may occlude some small bronchi. Also, the small airways are narrowed and show inflammatory changes. Reversible aspects include partial airway occlusion by excess secretions and airway narrowing secondary to smooth muscle contraction, bronchial wall edema and inflammation of the airways.


In asthma, chronic inflammatory processes in the airway play a central role in increasing the resistance to airflow within the lungs. Many cells and cellular elements are involved in the inflammatory process, particularly mast cells, eosinophils T lymphocytes, neutrophils, epithelial cells, and even airway smooth muscle itself. The reactions of these cells result in an associated increase in the existing sensitivity and hyper-responsiveness of the airway smooth muscle cells that line the airways to the particular stimuli involved.


The chronic nature of asthma can also lead to remodeling of the airway wall (i.e., structural changes such as thickening or edema) which can further affect the function of the airway wall and influence airway hyper-responsiveness. Other physiologic changes associated with asthma include excess mucus production, and if the asthma is severe, mucus plugging, as well as ongoing epithelial denudation and repair. Epithelial denudation exposes the underlying tissue to substances that would not normally come in contact with them, further reinforcing the cycle of cellular damage and inflammatory response.


In susceptible individuals, asthma symptoms include recurrent episodes of shortness of breath (dyspnea), wheezing, chest tightness, and cough. Currently, asthma is managed by a combination of stimulus avoidance and pharmacology.


Stimulus avoidance is accomplished via systematic identification and minimization of contact with each type of stimuli. It may, however, be impractical and not always helpful to avoid all potential stimuli.


Pharmacological management of asthma includes: (1) long term control through use of anti-inflammatories and long-acting bronchodilators and (2) short term management of acute exacerbations through use of short-acting bronchodilators. Both of these approaches require repeated and regular use of the prescribed drugs. High doses of corticosteroid anti-inflammatory drugs can have serious side effects that require careful management. In addition, some patients are resistant to steroid treatment. The difficulty involved in patient compliance with pharmacologic management and the difficulty of avoiding stimulus that triggers asthma are common barriers to successful asthma management. Current management techniques are thus neither completely successful nor free from side effects. Accordingly, it would be desirable to provide a system and method which improves airflow without the need for patient compliance.


Various energy delivering systems have been developed to intraluminally treat anatomical structures and lumen other than the lung airways. Unfortunately, the systems which are useful in treating such structures are generally not helpful in developing techniques to treat the lung airways because the lung airways are markedly different than other tissue structures. For example, lung airways are particularly heterogeneous. Variations in lung tissue structure occur for a number of reasons such as: the branching pattern of the tracheobronchial tree leads to local variation in the size and presence of airways; the vasculature of the lungs is a similar distributed network causing variation in size and presence of blood vessels; within the airways are variable amounts of differing structures such as cartilage, airway smooth muscle, and mucus glands and ducts; and energy delivery may also be influenced differently at the periphery, near the outer surface of a lung lobe, than in the central portion.


Lung airways also include a number of protruding folds. Other tissue structures such as blood vessels typically do not have the folds found in airways. Airways contain mucous and air whereas other structures contain different substances. The tissue chemistry between various lumens and airways is also different. In view of these differences, it is not surprising that conventional energy delivering systems cannot be universally applied to treat all tissue structures. Moreover, power shut-offs and other safety mechanisms must be precisely tailored to specific tissue so that the tissue is not harmed by application of excess energy.


Accordingly, an intraluminal RF energy delivering system that is capable of safely delivering RF energy to lung airways is desired. In particular, a system which is capable of controlling the temperature when treating an airway of an asthma or COPD patient is desired. It is also desirable to provide a system having built-in safeguards that shut the power off thereby preventing damage to the subject tissue or collateral tissue.


SUMMARY OF THE INVENTION

The present invention includes a system for delivering energy to an airway wall of a lung comprising an energy delivering apparatus and a PID controller. The energy delivering apparatus may include a flexible elongated member and a distal expandable basket having at least one electrode for transferring energy to the airway wall and at least one temperature sensor for measuring temperature (TM) of the airway wall when energy is delivered to the airway wall. The system further comprises a PID controller for determining a new power set point (Pi+1) based on an error (e) between a preset temperature (TS) and the measured temperature wherein the PID controller applies an algorithm having a variable gain factor (G).


In one variation of the present invention, the algorithm is Pi+1=Pi+G(αei+βei−1+γei−2) where α, β and γ are preset values. For instance, in one variation of the present invention, α is from 1 to 2; β is from −1 to −2; and γ is from −0.5 to 0.5. In another variation of the present invention, α, β, γ are 1.6, −1.6, and 0.0 respectively.


In another variation of the present invention, the gain factor used in the PID algorithm is reset 0.1 to 2 seconds after energy delivery has begun. The gain factor can also be reset 0.5 seconds after energy delivery has begun. The invention includes resetting G to 0.9 to 1.0 if a temperature rise in ° C. per Joule is less than or equal to 2.5; 0.4 to 0.5 if a temperature rise in ° C. per Joule is between 2.5 to 5.0; to 0.2 to 0.3 if a temperature rise in ° C. per Joule is equal to 5.0 to 7.5; and to 0.1 to 0.2 if a temperature rise in ° C. per Joule is greater than 7.5. Initially, the gain factor is equal to 0.4 to 0.5 and preferably 0.45 to 0.47.


In another variation of the present invention, the PID algorithm is Pi+1=Pi+(G1ei+G2ei−1+G3ei−2) and G1, G2 and G3 are variable gain factors. The invention includes configuring the controller such that G1, G2 and G3 are reset to 0.9 to 2.00, −0.9 to −2.00 and 0.5 to −0.5 respectively if a temperature rise in ° C. per Joule is less than or equal to 2.5; to 0.40 to 1.00, −0.40 to −1.00 and 0.25 to −0.25 respectively if a temperature rise in ° C. per Joule is between 2.5 to 5.0; to 0.20 to 0.60, −0.20 to −0.60 and 0.15 to −0.15 respectively if a temperature rise in ° C. per Joule is equal to 5.0 to 7.5; and to 0.10 to 0.40, −0.10 to −0.40 and 0.10 to −0.10 respectively if a temperature rise in ° C. per Joule is greater than 7.5. Each of the variable gain factors may be equal to a product of at least one preset value and at least one variable value.


In another variation of the present invention, the controller is configured such that the energy delivery is terminated if the energy delivered exceeds a maximum energy such as 120 joules.


In another variation of the present invention, the controller is configured to deliver energy for an activation time period such as up to 15 seconds, 8 to 12 seconds, or 10 seconds.


In another variation of the present invention, the controller is configured such that TS is set at a value between 60 to 80° C., or 65° C.


In another variation of the present invention, the controller is configured to measure impedance and said energy delivery is terminated when said impedance drops below a preset impedance value such as 40 to 60 ohms.


In another variation of the present invention, the controller is configured to terminate the energy delivery if TM exceeds TS by a pre-selected value such as 10, 15 or 20° C.


In another variation of the present invention, the controller is configured to terminate the energy delivery if the output power is greater or equal to a nominal output power and TM drops by a critical temperature difference within a sampling period. The invention includes a nominal output power set at a value of at least 17 watts; the sampling period is set at a value of at least 0.5 seconds; and the critical temperature difference is 2° C.


In another variation of the present invention, the controller is configured to terminate the energy delivery if said TM averaged over a time window exceeds TS by a fixed temperature difference. The fixed temperature difference may be a value between 1 and 10° C. or 5° C. The time window is between 1 and 5 seconds or 2 seconds.


In another variation of the present invention, the controller is configured to terminate if the measured temperature drops by 10 or more ° C. in a sample period such as 1.0 seconds or 0.2 seconds.


Another variation of the present invention is a method for treating a lung by transferring energy from an active region of an energy delivery apparatus to an airway wall of the lung. The energy delivery apparatus includes a flexible elongate body and a distal section and the active region is located in the distal section. The energy delivery apparatus further has a temperature sensor located in the distal section for measuring a temperature (TM) of said airway wall and the method comprises the following steps: setting a preset temperature (TS); determining a power set point (Pi) to deliver energy from the active region to the target medium; measuring the TM using the temperature sensor; and determining a new power set point (Pi+1) based on an error (e) between the preset temperature (TS) and the measured temperature (TM) using a PID algorithm.


In yet another variation of the present invention, a process for transferring energy to a target medium using an energy delivery apparatus is provided. The energy delivery apparatus includes a flexible elongate body and a distal section wherein the distal section includes an expandable basket with at least one active region for transferring energy to the target medium. The energy delivery apparatus further has a temperature sensor located in the distal section for measuring a temperature (TM) of the target medium. The process comprises the following steps: setting a preset temperature (TS); determining a power set point (Pi) to deliver energy from the active region to the target medium; measuring TM using the temperature sensor; and determining a new power set point (Pi+1) based on an error (e) between the preset temperature (TS) and the measured temperature (TM) using an algorithm having a variable gain factor. The energy may be delivered to an airway wall of a lung in vivo, in vitro or to another target such as a sponge or towel which may be moistened with saline solution. Saline solution increases the conductivity of the target.


In one variation of the present invention, the algorithm is Pi+1=Pi+G(αei+βei−1+γei−2) where α, β and γ are preset values: α is from 1 to 2; β is from −1 to −2; and γ is from −0.5 to 0.5. In another variation of the present invention, α, β, γ are 1.6, −1.6, and 0.0 respectively.


In another variation of the present invention, the gain factor is reset 0.1 to 2 seconds after energy delivery has begun. The gain factor can also be reset 0.5 seconds after energy delivery has begun. The invention includes resetting G to 0.9 to 1.0 if a temperature rise in ° C. per Joule is less than or equal to 2.5; 0.4 to 0.5 if a temperature rise in ° C. per Joule is between 2.5 to 5.0; to 0.2 to 0.3 if a temperature rise in ° C. per Joule is equal to 5.0 to 7.5; and to 0.1 to 0.2 if a temperature rise in ° C. per Joule is greater than 7.5. Initially, the gain factor is equal to 0.4 to 0.5 and preferably 0.45 to 0.47.


In another variation of the present invention, the energy delivery is terminated if the energy delivered exceeds a maximum energy such as 120 joules.


In another variation of the present invention, energy is delivered for an activation time period such as 0 to 15 seconds, 8 to 12 seconds, or 10 seconds.


In another variation of the present invention, TS is set at a value between 60 to 80, or 65° C.


In another variation of the present invention, impedance is measured and energy delivery is terminated when the impedance drops below a preset impedance value such as 40 to 60 ohms.


In another variation of the present invention, the energy is terminated if TM exceeds TS by a pre-selected value such as 10, 15 or 20° C.


In another variation of the present invention, energy is terminated if the output power is greater or equal to a nominal output power and TM drops by a critical temperature difference within a sampling period. In variations of the present invention, the nominal output power is set at a value of at least 17 watts; the sampling period is set at a value of at least 0.5 seconds; and the critical temperature difference is 2° C.


In another variation, the energy delivery apparatus is configured to deliver an amount of power up to a maximum power. The maximum power can be from 10 to 40 watts and preferably from 15 to 20 watts.


In another variation of the present invention, energy delivery is terminated if TM averaged over a time window exceeds TS by a fixed temperature difference. The fixed temperature difference may be a value between 1 and 10° C. or 5° C. The time window is between 1 and 5 seconds or 2 seconds.


In another variation of the present invention, the energy delivery is terminated if the measured temperature drops by 10 or more ° C. in a sample period such as 1.0 seconds or 0.2 seconds.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described in greater detail with reference to the various embodiments illustrated in the accompanying drawings:



FIG. 1 is a block diagram of a feedback loop of the present invention.



FIG. 2A is a cross sectional view of a medium sized bronchus in a healthy patient.



FIG. 2B is a cross sectional view of a bronchiole in a healthy patient.



FIG. 3 is a cross sectional view of the bronchus of FIG. 2A showing the remodeling and constriction occurring in an asthma patient.



FIG. 4 is an illustration of the lungs being treated with a device and controller according to the present invention.



FIG. 5A is an illustration of an energy delivery device in accordance with the present invention.



FIGS. 5B-5D show a partial view of a thermocouple attached to a basket leg in accordance with the present invention.





DETAILED DESCRIPTION

The present invention includes a controller and an energy deliver apparatus to deliver energy to the airway walls of the lungs. Amongst other features, the controller includes a feedback loop having a variable gain factor as diagramed in FIG. 1. The system is useful in treating asthma and various symptoms of reversible obstructive pulmonary disease. Examples of suitable applications and methods are disclosed in International Application No. PCT/US00/28745 filed Oct. 17, 2000.


The present invention is particularly useful in treating lung tissue. This is surprising in view of the unique and complicated structure of lung tissue. Referring first to FIGS. 2A and 2B, a cross section of two different airways in a healthy patient is shown. The airway of FIG. 2A is a medium sized bronchus having an airway diameter D1 of about 3 mm. FIG. 2B shows a section through a bronchiole having an airway diameter D2 of about 1.5 mm. Each airway includes a folded inner surface or epithelium 10 surrounded by stroma 12 and smooth muscle tissue 14. The larger airways including the bronchus shown in FIG. 2A also have mucous glands 16 and cartilage 18 surrounding the smooth muscle tissue 14. Nerve fibers 20 and blood vessels 24 surround the airway. The airway is thus quite different from other tissues such as blood vessel tissue which does not include such folds, cartilage or mucous glands. In contrast, FIG. 3 illustrates the bronchus of FIG. 2A in which the smooth muscle 14 has hypertrophied and increased in thickness causing the airway diameter to be reduced from the diameter D1 to a diameter D3. Accordingly, the airways to be treated with the device of the present invention may be 1 mm in diameter or greater, more preferably 3 mm in diameter or greater.



FIG. 4 is an illustration of the lungs being treated with a system 36 according to the present invention. The system 36 includes a controller 32 and an energy treatment device 30 which may be an elongated member as described further below. The device 30 also includes an expandable distal section which can be positioned at a treatment site 34 within a lung or another target medium. In operation, the device is manipulated to the treatment site 34. RF energy, for example, is delivered through the energy delivering device and penetrates the surface of the lung tissue such that tissue is affected below the epithelial layer as well as on the surface of the lung tissue.


Energy Delivering Device


As indicated above, the present invention includes a controller 32 and a device 30 through which it delivers energy to the target medium 34. A device 30 of the present invention should be of a size to access the bronchus or bronchioles of the human lung. The device may be sized to fit within bronchoscopes, preferably, with bronchoscopes having a working channel of 2 mm or less. The device may also include a steering member configured to guide the device to a desired target location. For example, this steering member may deflect a distal tip of the device in a desired direction to navigate to a desired bronchi or bronchiole.


The energy delivering apparatus 30 typically includes an elongate body having a proximal section and a distal section. The distal section features a radially expandable basket having a plurality of legs. The legs may be electrodes or have an active region defined by an insulated covering which contacts the medium to be treated. The basket is expanded with an actuator mechanism which may be provided in a handle attached to proximal end of the elongate body. Examples of energy delivering devices in accordance with the present invention are described in co-pending U.S. application Ser. No. 09/436,455 filed Nov. 8, 1999 which is hereby incorporated by reference in its entirety.


Temperature Sensor


The invention also includes a temperature detecting element. Examples of temperature detecting elements include thermocouples, infrared sensors, thermistors, resistance temperature detectors (RTDs), or any other apparatus capable of detecting temperatures or changes in temperature. The temperature detecting element is preferably placed in proximity to the expandable member.



FIG. 5A is a partial view of a variation of the invention having thermocouple 137 positioned about midway along basket leg 106. FIG. 5B is an enlarged partial view of the thermocouple 137 of FIG. 5A showing the leads 139 separately coupled on an inwardly-facing surface of the leg 106. Consequently, the basket leg itself is used as part of the thermocouple junction upon which the temperature measurement is based. In other words, the thermocouple junction is intrinsic to the basket leg. This configuration is preferred because it provides an accurate temperature measurement of tissue contacting the leg 106 in the vicinity of the thermocouple leads. In contrast, typical thermocouple configurations consist of a thermocouple junction offset or extrinsic to the basket leg. We believe that thermocouple junctions having an offset from or extrinsic to the basket leg do not measure temperature as accurately in certain applications as thermocouple junctions which are intrinsic to the basket leg.


The leads 139 may be placed at other locations along the leg 106 including an edge 405. Joining the leads 139 to the edge 405, however, is undesirable because of its relatively small bonding surface.



FIG. 5B also shows basket leg 106 having an outer insulating material or coating 410. The boundaries 415 of the insulating material 410 define an uninsulated, active section of electrode leg 106 which delivers energy to the tissue walls. Preferably, the insulating coating 410 is heat shrink tubing or a polymeric coating. However, other insulating materials may be used.



FIGS. 5C and 5D show another variation of the present invention having thin foil or laminated thermocouple leads 139. The thermocouple leads 139 are configured as foils or layers which can be, for example, prefabricated foils or sputtered films. Suitable materials for the thermocouple leads (listed in pairs) include, but are not limited to: Constantan and Copper; Constantan and Nickel-Chromium; Constantan and Iron; and Nickel-Aluminum and Nickel-Chromium. The thermocouple pair, CHROMEL and ALUMEL (both of which are registered trademarks of Hoskins Manufacturing) is preferred. CHROMEL and ALUMEL is a standard thermocouple pair and has been shown to be biocompatible and corrosion resistant in our applications. The thermocouple leads 139 may be placed such that each lead approaches the center of the basket leg from an opposite end of the basket leg. The leads 139 then terminate in bond joints 440 and 450. Alternatively, as shown in the configuration of FIG. 5D, both thermocouple leads 139 may run from the same end of the basket leg 106.


Preferably, insulating layers 430 and 440 are disposed between the thin film leads 139 and the basket leg 106. The insulating layers 430 and 440 electrically separate the leads 139 as well as electrically separate the leads from the leg 106. The insulating layers 430 and 440 limit the thermocouple junction to bond joints 450 and 460, which are optimally positioned on active region 420 of basket leg 106.


Controller


The present invention includes a controller which controls the energy to be delivered to the airways via an energy transfer device. The controller includes at least one of the novel features disclosed hereinafter and may also incorporate features in known RF energy controllers. An example of a RF generator which may be modified in accordance with the present invention is the FORCE™ 2 Generator manufactured by Valleylab, Boulder, Colo., U.S.A. Another suitable technique to generate and control RF energy is to modulate RF output of a RF power amplifier by feeding it a suitable control signal.


The controller and power supply is configured to deliver enough energy to produce a desired effect in the lung. The power supply should also be configured to deliver the energy for a sufficient duration such that the effect persists. This is accomplished by a time setting which may be entered into the power supply memory by a user.


The power supply or generator of the present invention can also employ a number of algorithms to adjust energy delivery, to compensate for device failures (such as thermocouple detachment), to compensate for improper use (such as poor contact of the electrodes), and to compensate for tissue inhomogeneities which can affect energy delivery such as, for example, subsurface vessels, adjacent airways, or variations in connective tissue.


The power supply can also include circuitry for monitoring parameters of energy transfer: (for example, voltage, current, power, impedance, as well as temperature from the temperature sensing element), and use this information to control the amount of energy delivered. In the case of delivering RF energy, typical frequencies of the RF energy or RF power waveform are from 300 to 1750 kHz with 300 to 500 kHz or 450 to 475 being preferred. The RF power-level generally ranges from about 0-30 W but depends upon a number of factors such as, size of the electrodes. The controller may also be configured to independently and selectively apply energy to one or more of the basket leg electrodes.


A power supply may also include control modes for delivering energy safely and effectively. Energy may be delivered in open loop (power held constant) mode for a specific time duration. Energy may also be delivered in temperature control mode, with output power varied to maintain a certain temperature for a specific time duration. In the case of RF energy delivery via RF electrodes, the power supply may also operate in impedance control mode.


Temperature Control Mode


In a temperature control mode, the power supply may operate up to a 75° C. setting. That is, the temperature measured by the thermocouple can reach up to 75° C. before the power supply is shut off. The duration must be long enough to produce the desired effect, but as short as possible to allow treatment of all of the desired target airways within a lung. For example, up to 15 seconds is suitable, and more preferably 8 to 12 seconds with about 10 seconds per activation (while the device is stationary) being preferred. Shorter duration with higher temperature will also produce an acceptable acute effect.


It should be noted that different device constructions utilize different parameter settings to achieve the desired effect. For example, while direct RF electrodes typically utilize temperatures up to 75° C. in temperature control mode, resistively heated electrodes may utilize temperatures up to 90° C.


Energy Pulses and Energy Modulation


Short bursts or pulses of RF energy may also be delivered to the target tissue. Short pulses of RF energy heat the proximal tissue while the deeper tissue, which is primarily heated by conduction through the proximal tissue, cools between the bursts of energy. Short pulses of energy therefore tend to isolate treatment to the proximal tissue.


The application of short pulses of RF energy may be accomplished by modulating the RF power waveform with a modulation waveform. Modulating the RF power waveform may be performed while employing any of the other control algorithms discussed herein so long as they are not exclusive of one another. For example, the RF energy may be modulated while in a temperature control mode.


Examples of modulation waveforms include but are not limited to a pulse train of square waves, sinusoidal, or any other waveform types. In the case of square wave modulation, the modulated RF energy can be characterized in terms of a pulse width (the time of an individual pulse of RF energy) and a duty cycle (the percent of time the RF output is applied). A suitable duty cycle can be up to 100% which is essentially applying RF energy without modulation. Duty cycles up to 80% or up to 50% may also be suitable for limiting collateral damage or to localize the affect of the applied energy.


Feedback Algorithm


As indicated above, the present invention includes controllers having various algorithms. The algorithms may be either analog and digital based. A preferred embodiment is a three parameter controller, or Proportional-Integral-Derivative (PID) controller which employs the following algorithm: Pi+1=Pi+G(αei+βei−1+γei−2) where Pi+1 is a new power set point, Pi is a previous power set point, α, β and γ are preset values, G is a variable gain factor and ei, ei−1, ei−2 correspond to error at the present time step, error one step previous and error two steps previous where the error is the difference between the preset temperature and a measured temperature.


We have found that by using a variable gain factor (G) to adaptively control RF energy delivery, the system of the present invention can treat a wide range of tissue types including lung tissue bronchus, bronchioles and other airway passages. The variable gain factor scales the coefficients (alpha, beta, and gamma; each a function of the three PID parameters) based on, for example, the temperature response to energy input during the initial temperature ramp up.


Exemplary PID parameters are presented herein, expressed in alpha-beta-gamma space, for an energy delivering device and controller of the present invention. These settings and timings are based on testing in various animal lung tissues using an energy delivering apparatus as described above. First, the gain factor preferably varies and is reset 0.1 to 2 and more preferably at 0.5 seconds after energy delivery has begun. Preferably, the gain factor is reset as follows: G is reset to 0.9 to 1.0 and preferably 0.9 if a temperature rise in ° C. per Joule is less than or equal to 2.5; G is reset to 0.4 to 0.5 and preferably 0.5 if a temperature rise in ° C. per Joule is between 2.5 to 5.0; G is reset to 0.2 to 0.3 and preferably 0.2 if a temperature rise in ° C. per Joule is equal to 5.0 to 7.5; and G is reset to 0.1 to 0.2 and preferably 0.1 if a temperature rise in ° C. per Joule is greater than 7.5. We have also found that a suitable value for α is from 1 to 2; for β is from −1 to −2; and for γ is from −0.5 to 0.5. More preferably α, β, γ are 1.6, −1.6, and 0.0 respectively.


It is also possible to change the relative weights of alpha, beta, and gamma depending upon monitored temperature response working in either PID or Alpha-Beta-Gamma coordinate space beyond just scaling the alpha-beta-gamma coefficients with a variable gain factor. This can be done by individually adjusting any or all of alpha, beta, or gamma.


In another variation of the present invention, the PID algorithm is Pi+1=Pi+(G1ei+G2ei−1+G3ei−2) and G1, G2 and G3 are each variable gain factors. The invention includes configuring the controller such that G1, G2 and G3 are reset to 0.90 to 2.00, −0.90 to −2.00 and 0.50 to −0.50 respectively if a temperature rise in ° C. per Joule is less than or equal to 2.5; to 0.40 to 1.00, −0.40 to −1.00 and 0.25 to −0.25 respectively if a temperature rise in ° C. per Joule is between 2.5 to 5.0; to 0.20 to 0.60, −0.20 to −0.60 and 0.15 to −0.15 respectively if a temperature rise in ° C. per Joule is equal to 5.0 to 7.5; and to 0.10 to 0.40, −0.10 to −0.40 and 0.10 to −0.10 respectively if a temperature rise in ° C. per Joule is greater than 7.5. Each of the variable gain factors may be equal to a product of at least one preset value and at least one variable value.


It is also possible to employ an algorithm that continuously adapts to signals rather than at discrete sample steps, intervals or periods. The algorithm takes into account several variables upon which observed temperature response depends including, for example: initial temperature, time history of energy delivery, and the amount of energy required to maintain set point temperature. An exemplary analog PID algorithm is: u=KP e+KI∫ edt+KD(de/dt) where u is a signal to be adjusted such as, for example, a current, a voltage difference, or an output power which results in energy delivery from the electrode to the airway wall. KP, KI and KD are preset or variable values which are multiplied with the proper error term where e(t) is the difference between a preset variable and a measured process variable such as temperature at time (t). The above equation is suitable for continuous and/or analog type controllers.


Power Shut Down Safety Algorithms


In addition to the control modes specified above, the power supply may include control algorithms to limit excessive thermal damage to the airway tissue. Damage may be limited by terminating or shutting down the energy being delivered to the target medium. The algorithms can be based on the expectation that the sensed temperature of the tissue will respond upon the application of energy. The temperature response, for example, may be a change in temperature in a specified time or the rate of change of temperature. The expected temperature response can be predicted as a function of the initially sensed temperature, the temperature data for a specified power level as a function of time, or any other variables found to affect tissue properties. The expected temperature response may thus be used as a parameter in a power supply safety algorithm. For example, if the measured temperature response is not within a predefined range of the expected temperature response, the power supply will automatically shut down.


Other control algorithms may also be employed. For example, an algorithm may be employed to shut down energy delivery if the sensed temperature does not rise by a certain number of degrees in a pre-specified amount of time after energy delivery begins. Preferably, if the sensed temperature does not increase more than about 10° C. in about 3 seconds, the power supply is shut off. More preferably, if the sensed temperature does not increase more than about 10° C. in about 1 second, the power supply is shut off.


Another way to stop energy delivery includes shutting down a power supply if the temperature ramp is not within a predefined range at any time during energy delivery. For example, if the measured rate of temperature change does not reach a predefined value, the power supply will stop delivery of the RF energy. The predefined values are predetermined and based on empirical data. Generally, the predefined values are based on the duration of time RF energy is delivered and the power-level applied. A suitable predefined rate of temperature change to stop energy delivery is from 8° C./second to 15° C./second in the first 5 seconds (preferably in the first 2 seconds) of commencing energy delivery.


Other algorithms include shutting down a power supply if a maximum temperature setting is exceeded or shutting down a power supply if the sensed temperature suddenly changes, such a change includes either a drop or rise, this change may indicate failure of the temperature sensing element. For example, the generator or power supply may be programmed to shut off if the sensed temperature drops more than about 10° C. in about 0.1 to 1 seconds and more preferably in about 0.2 seconds.


In another configuration, the power is terminated when the measured temperature exceeds a pre-selected temperature or exceeds the set point temperature by a pre-selected amount. For example, when the set point is exceeded by 5 to 20° C., more preferably 15° C. the power will terminate.


In another configuration, power is terminated when the measured temperature (averaged over a time window) exceeds a pre-selected temperature. For example, power may be terminated when the measured temperature (averaged over 1 to 5 seconds and preferably averaged over 2 seconds) exceeds the preset temperature by a predetermined amount. The predetermined amount is generally from 1 to 10° C. and preferably about 5° C. Suitable preset temperatures are from 60 to 80° C. and most preferably about 65° C. Accordingly, in one exemplary configuration, the power is stopped when the measured temperature (averaged over 2 seconds) exceeds 70° C.


In another configuration, the power is terminated when the amount of energy delivered exceeds a maximum amount. A suitable maximum amount is 120 Joules for an energy delivery apparatus delivering energy to the airways of lungs.


In another configuration, the power is shut down depending on an impedance measurement. The impedance is monitored across a treated area of tissue within the lung. Impedance may also be monitored at more than one site within the lungs. The measuring of impedance may be but is not necessarily performed by the same electrodes used to deliver the energy treatment to the tissue. The impedance may be measured as is known in the art and as taught in U.S. application Ser. No. 09/436,455 which is incorporated by reference in its entirety. Accordingly, in one variation of the present invention, the power is adjusted or shut off when a measured impedance drops below a preset impedance value. When using the energy delivering device of the present invention to treat airways, a suitable range for the preset impedance value is from 40 to 60 ohms and preferably about 50 ohms.


In another variation, the energy delivery apparatus is configured to deliver an amount of power up to a maximum power. The maximum power can be from 10 to 40 watts and preferably from 15 to 20 watts.


In yet another configuration, the power supply is configured to shut down if the power delivered exceeds a maximum power and the measured temperature drops by a critical temperature difference within a sampling period of time. A suitable maximum power is from 15 to 20 Watts and preferably about 17 watts. The sampling period of time generally ranges from 0.1 to 1.0 seconds and preferably is about 0.5 seconds. A suitable range for the critical temperature difference is about 2° C.


It is to be understood that any of the above algorithms and shut-down configurations may be combined in a single controller. However, algorithms having mutually exclusive functions may not be combined.


While the power supply or generator preferably includes or employs a microprocessor, the invention is not so limited. Other means known in the art may be employed. For example, the generator may be hardwired to run one or more of the above discussed algorithms.


The controller is preferably programmable and configured to receive and manipulate other signals than the examples provided above. For example, other useful sensors may provide input signals to the processor to be used in determining the power output for the next step. The treatment of an airway may also involve placing a visualization system such as an endoscope or bronchoscope into the airways. The treatment device is then inserted through or next to the bronchoscope or endoscope while visualizing the airways. Alternatively, the visualization system may be built directly into the treatment device using fiber optic imaging and lenses or a CCD and lens arranged at the distal portion of the treatment device. The treatment device may also be positioned using radiographic visualization such as fluoroscopy or other external visualization means.


EXAMPLES

A system to treat airways in accordance with the present invention was built and tested in vivo on two canines. The system included an energy delivering apparatus having a distal basket. The basket included electrode legs and a temperature sensor mounted to one of the legs. The system also included a generator programmed to measure the temperature change per energy unit during the first half-second of treatment. A PID gain factor was adjusted depending on the measured tissue response. That is, the gain factor was adjusted based on the temperature change per joule output during the first half second. In general, this corresponds to a higher gain for less responsive tissue and lower gain for more responsive tissue.


After treating the test subjects with a general anesthetic, RF energy was delivered to target regions using an energy delivery device and generator as described above. In particular, energy activations were performed on all available intraparenchymal airways three millimeters or larger in diameter in both lungs. Three hundred sixty-three activations using a 65° C. temperature setting were performed in the two animals (i.e., 180 activations per animal). Additionally, in twenty of the activations in each animal, the energy delivery device was deliberately deployed improperly to provide a “Stress” condition.


In each activation, the measured temperature reached and stabilized at 65° C. or, in the case of the twenty activations under “stress” conditions, the power properly shut off. Thus, the present invention can successfully treat lung tissue with a variable gain setting and various safety algorithms to safely maintain a preset temperature at the electrode or lung tissue surface. This temperature control is particularly advantageous when treating the airways of lungs to reduce asthma symptoms.


This invention has been described and specific embodiments or examples of the invention have been portrayed to convey a proper understanding of the invention. The use of such examples is not intended to limit the invention in any way. Additionally, to the extent that there are variations of the invention which are within the spirit of the disclosure and are equivalent to features found in the claims, it is the intent that the claims cover those variations as well. All equivalents are considered to be within the scope of the claimed invention, even those which may not have been set forth herein merely for the sake of brevity. Also, the various aspects of the invention described herein may be modified and/or used in combination with such other aspects also described to be part of the invention either explicitly or inherently to form other advantageous variations considered to be part of the invention covered by the claims which follow.


The invention described herein expressly incorporates the following co-pending applications by reference in their entirety: U.S. application Ser. Nos. 09/095,323; 09/095,323; 09/349,715; 09/296,040; 09/436,455; and U.S. application Ser. No. 09/535,856.

Claims
  • 1. A method for treating a lung by transferring energy from an active region of an energy delivery apparatus to an airway wall of said lung, said energy delivery apparatus having a flexible elongate body and a distal section and said active region being located in said distal section, said energy delivery apparatus further having a temperature sensor located in said distal section for measuring a temperature (TM) of said airway wall, said method comprising: setting a preset temperature (Ts);determining a power set point (Pi) to deliver energy from said active region to said target medium;measuring said TM using said temperature sensor;determining a new power set point (Pi+1) based on an error (e) between said preset temperature (Ts) and said measured temperature (TM) using a PID algorithm; andterminating said energy delivery when the temperature does not rise a predetermined amount in a specified period of time.
  • 2. The process of claim 1 comprising terminating said energy delivery if said energy delivered exceeds a maximum energy.
  • 3. The process of claim 2 wherein said maximum energy is 120joules.
  • 4. The process of claim 1 further comprising measuring impedance and terminating said energy delivery when said impedance, drops below a preset impedance value.
  • 5. The process of claim 4 wherein said preset impedance value is from 40 to 60 ohms.
  • 6. The process of claim 1 comprising terminating said energy delivery if said TM exceeds Ts by a pre-selected value.
  • 7. The process of claim 6 wherein said pre-selected value is 10° C.
  • 8. The process of claim 6 wherein said pre-selected value is 15° C.
  • 9. The process of claim 6 wherein said pre-selected value is 20° C.
  • 10. The process of claim 1 wherein said delivering energy to a target medium is performed by delivering energy to an airway wall of a lung in vivo.
  • 11. The process of claim 1 wherein the power is terminated when the temperature does not rise by more than about 10° C. in about 3 seconds.
  • 12. The process of claim 1 wherein the power is terminated when the temperature does not rise by more than about 10° C. in about 1 second.
  • 13. A process for transferring energy to a target medium using an energy delivery apparatus, said energy delivery apparatus having a flexible elongate body and a distal section wherein said distal section includes an expandable basket with at least one active region for transferring energy to said target medium, said energy delivery apparatus further having a temperature sensor located in said distal section for measuring a temperature (TM) of said target medium, said process comprising: setting a preset temperature (Ts);determining a power set point (Pi) to deliver energy from said active region to said target medium;measuring said TM using said temperature sensor;determining a new power set point (Pi+1) based on an error (e) between said preset temperature (Ts) and said measured temperature (TM) using an algorithm having a variable gain factor, wherein said algorithm is:Pi +1=Pi+G(αei+βei-1+γei-2) where α, β and γ are preset values, and wherein at least one of α, β and γ is from −0.5 to 0.5.
  • 14. The process of claim 13 wherein the algorithm further includes a gain factor (G).
  • 15. The process of claim 14 comprising resetting G 0.1 to 2seconds after energy delivery has begun.
  • 16. The process of claim 15 comprising resetting G 0.5 seconds after energy delivery has begun.
  • 17. The process of claim 16 comprising resetting G to 0.9 to 1.0 if a temperature rise in ° C. per Joule is less than or equal to 2.5.
  • 18. The process of claim 16 comprising resetting G to 0.4 to 0.5 if a temperature rise in ° C. per Joule is between 2.5 to 5.0.
  • 19. The process of claim 16 comprising resetting G to 0.2 to 0.3 if a temperature rise in ° C. per Joule is equal to 5.0 to 7.5.
  • 20. The process of claim 16 comprising resetting G to 0.1 to 0.2 if a temperature rise in ° C. per Joule is greater than 7.5.
  • 21. The process of claim 13 comprising setting α between 1 and 2.
  • 22. The process of claim 21 comprising setting β between −1 to −2.
  • 23. The process of claim 13 comprising setting α, β, γ to 1.6, −1.6, and 0.0 respectively.
  • 24. The process of claim 13 wherein energy is delivered for an activation period.
  • 25. The process of claim 24 wherein said activation period up to 15seconds.
  • 26. The process of claim 25 wherein said activation period is 8 to 12 seconds.
  • 27. The process of claim 26 wherein said activation period is 10seconds.
  • 28. The process of claim 13 comprising setting Ts at a value between 60 to 80° C.
  • 29. The process of claim 28 comprising setting Ts at 65° C.
  • 30. The process of claim 13 wherein said delivering energy to a target medium is performed by delivering energy to an airway wall of an excised lung.
  • 31. The process of claim 13 wherein said delivering energy to a target medium is performed by delivering energy to a sponge or towel.
  • 32. The process of claim 13 wherein the energy delivery apparatus is configured to deliver an amount of power up to a maximum power.
  • 33. The process of claim 32 wherein the maximum power is 10 to 40 watts.
  • 34. The process of claim 33 wherein the maximum power is 15 to 20 watts.
  • 35. A process for transferring energy to a target medium using an energy delivery apparatus, said energy delivery apparatus having a flexible elongate body and a distal section wherein said distal section includes an expandable basket with at least one active region for transferring energy to said target medium, said energy delivery apparatus further having a temperature sensor located in said distal section for measuring a temperature (TM) of said target medium, said process comprising: setting a preset (Ts);determining a power set point (Pi) to deliver energy from said active region to said target medium;measuring said TM using said temperature sensor;determining a new power set point (Pi+1 )based on an error (e) between said preset temperature (Ts) and said measured temperature(TM) using an algorithm having a variable gain factor; andterminating said energy delivery if an output power is greater or equal to a nominal output power and said TM drops by a critical temperature difference within a sampling period.
  • 36. The process of claim 35 wherein said nominal output power is set at a value of at least 17 watts.
  • 37. The process of claim 36 wherein said sampling period is set at a value of at least 0.5 seconds.
  • 38. The process of claim 37 wherein said critical temperature difference is 2° C.
  • 39. A process for transferring energy to a target medium using an energy delivery apparatus, said energy delivery apparatus having a flexible elongate body and a distal section wherein said distal section includes an expandable basket with at least one active region for transferring energy to said target medium, said energy delivery apparatus further having a temperature sensor located in said distal section for measuring a temperature (TM) of said target medium, said process comprising: setting a preset(Ts);determining a power set point (Pi)to deliver energy from said active region to said target medium;measuring said TM using said temperature sensor;determining a new power set point (Pi+1)based on an error (e) between said preset temperature (TS) and said measured temperature (TM)using an algorithm having a variable gain factor: andterminating said energy delivery if said TM averaged over a time window exceeds TS by a fixed temperature difference.
  • 40. The process of claim 39 wherein said fixed temperature difference is a value between 1 and 10° C.
  • 41. The process of claim 40 wherein said fixed temperature difference is 5° C.
  • 42. The process of claim 41 wherein said time window is between 1and 5 seconds.
  • 43. The process of claim 42 wherein said time window is 2seconds.
  • 44. A process for transferring energy to a target medium using an energy delivery apparatus, said energy delivery apparatus having a flexible elongate body and a distal section wherein said distal section includes an expandable basket with at least one active region for transferring energy to said target medium, said energy delivery apparatus further having a temperature sensor located in said distal section for measuring a temperature (TM) of said target medium, said process comprising: setting temperature (Ts);determining a power set point (Pi) to deliver energy from said active region to said target medium;measuring said TM using said temperature sensor;determining a new power set point (Pi+1) based on an error (e) between said preset temperature (Ts) and said measured temperature (TM) using an algorithm having a variable gain factor; andwherein said algorithm is Pi+1=Pi+(G1ei+G2ei-1+G3ei-2) where G1, G2 and G3 are variable gain factors.
  • 45. The process of claim 44 wherein said controller is configured such that said variable gain factors are reset 0.1 to 2 seconds after energy delivery has begun.
  • 46. The process of claim 45 wherein said controller is configured such that said variable gain factors are reset 0.5 seconds after energy delivery has begun.
  • 47. The process of claim 46 wherein said controller is configured such that G1, G2 and G3 are reset to 0.90 to 2.00, −0.90 to −2.00 and 0.50 to −0.50respectively if a temperature rise in ° C. per Joule is less than or equal to 2.5.
  • 48. The process of claim 46 wherein said controller is configured such that G1, G2 and G3 are reset to 0.40 to 1.00, −0.40 to −1.00 and 0.25 to −0.25respectively if a temperature rise in ° C. per Joule is between 2.5 to 5.0.
  • 49. The process of claim 46 wherein said controller is configured such that G1, G2 and G3 are reset to 0.20 to 0.60, −0.20 to −0.60 and 0.15 to −0.15respectively if a temperature rise in ° C. per Joule is equal to 5.0 to 7.5.
  • 50. The process of claim 46 wherein said controller is configured such that G1, G2 and G3 are reset to 0.10 to 0.40, −0.10 to −0.40 and 0.10 to −0.10respectively if a temperature rise in ° C. per Joule is greater than 7.5.
  • 51. The process of claim 46 wherein each of said variable gain factors is equal to a product of at least one preset value and at least one variable value.
  • 52. A method for treating a lung by transferring energy from an active region of an energy delivery apparatus to an airway wall of said lung, said energy delivery apparatus having a flexible elongate body and a distal section and said active region being located in said distal section, said energy delivery apparatus further having a temperature sensor located in said distal section for measuring a temperature (TM) of said airway wall, said method comprising: setting a preset temperature (Ts);determining a power set point (Pi) to deliver energy from said active region to said target medium;delivering energy from the energy delivery apparatus to the airway wall during an energy delivery phase;measuring said TM using said temperature sensor;determining a new power set point (Pi+1) based on an error (e) between said preset temperature (Ts) and said measured temperature (TM) using a PID algorithm; andterminating said energy delivery when the temperature ramp rate is not within a predetermined range at a selected portion of the energy delivery phase.
  • 53. The method of claim 52 wherein the temperature ramp rate is 8-15° C. for the first 2-5 seconds of the energy delivery phase.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 10/414,411 filed Apr. 14, 2003, now U.S. Pat. No. 7,104,987, which is a continuation of International Patent Application No. PCT/US01/32321 filed Oct. 17, 2001 and is a continuation-in-part of International Patent Application No. PCT/US00/28745 filed Oct. 17, 2000, the contents of which are hereby incorporated in their entirety.

US Referenced Citations (516)
Number Name Date Kind
612724 Hamilton Oct 1898 A
1155169 Starkweather Sep 1915 A
1207479 Bisgaard Dec 1916 A
1216183 Swingle Feb 1917 A
2072346 Smith Mar 1937 A
3320957 Sokolik May 1967 A
3568659 Karnegis Mar 1971 A
3667476 Muller Jun 1972 A
3692029 Adair Sep 1972 A
3995617 Watkins et al. Dec 1976 A
4095602 Leveen Jun 1978 A
4116589 Rishton Sep 1978 A
4129129 Amrine Dec 1978 A
4154246 Leveen May 1979 A
4461283 Doi Jul 1984 A
4502490 Evans et al. Mar 1985 A
4503855 Maslanka Mar 1985 A
4512762 Spears Apr 1985 A
4522212 Gelinas et al. Jun 1985 A
4557272 Carr Dec 1985 A
4565200 Cosman Jan 1986 A
4567882 Heller Feb 1986 A
4584998 McGrail Apr 1986 A
4612934 Borkan Sep 1986 A
4621642 Chen Nov 1986 A
4621882 Krumme Nov 1986 A
4625712 Wampler Dec 1986 A
4643186 Rosen et al. Feb 1987 A
4646737 Hussein et al. Mar 1987 A
4674497 Ogasawara Jun 1987 A
4683890 Hewson Aug 1987 A
4704121 Moise Nov 1987 A
4706688 Don Michael et al. Nov 1987 A
4709698 Johnston et al. Dec 1987 A
4739759 Rexroth et al. Apr 1988 A
4754065 Levenson et al. Jun 1988 A
4754752 Ginsburg et al. Jul 1988 A
4765959 Fukasawa Aug 1988 A
4772112 Zider et al. Sep 1988 A
4773899 Spears Sep 1988 A
4779614 Moise Oct 1988 A
4784135 Blum et al. Nov 1988 A
4790305 Zoltan et al. Dec 1988 A
4799479 Spears Jan 1989 A
4802492 Grunstein Feb 1989 A
4817586 Wampler Apr 1989 A
4825871 Cansell May 1989 A
4827935 Geddes et al. May 1989 A
4846152 Wampler et al. Jul 1989 A
4862886 Clarke et al. Sep 1989 A
4895557 Moise et al. Jan 1990 A
4906229 Wampler Mar 1990 A
4907589 Cosman Mar 1990 A
4908012 Moise et al. Mar 1990 A
4920978 Colvin May 1990 A
4944722 Carriker et al. Jul 1990 A
4955377 Lennox et al. Sep 1990 A
4967765 Turner et al. Nov 1990 A
4969865 Hwang et al. Nov 1990 A
4976709 Sand Dec 1990 A
4985014 Orejola Jan 1991 A
4991603 Cohen et al. Feb 1991 A
5009636 Wortley et al. Apr 1991 A
5009936 Yamanaka et al. Apr 1991 A
5010892 Colvin et al. Apr 1991 A
5019075 Spears et al. May 1991 A
5027829 Larsen Jul 1991 A
5030645 Kollonitsch Jul 1991 A
5036848 Hewson Aug 1991 A
5053033 Clarke Oct 1991 A
5056519 Vince Oct 1991 A
5074860 Gregory et al. Dec 1991 A
5078716 Doll Jan 1992 A
5084044 Quint Jan 1992 A
5096916 Skupin Mar 1992 A
5100388 Behl et al. Mar 1992 A
5100423 Fearnot Mar 1992 A
5103804 Abele et al. Apr 1992 A
5105826 Smits et al. Apr 1992 A
5106360 Ishiwara et al. Apr 1992 A
5107830 Younes Apr 1992 A
5114423 Kasprzyk et al. May 1992 A
5116864 March et al. May 1992 A
5117828 Metzger et al. Jun 1992 A
5135517 McCoy Aug 1992 A
5152286 Sitko et al. Oct 1992 A
5165420 Strickland Nov 1992 A
5167223 Koros et al. Dec 1992 A
5170803 Hewson et al. Dec 1992 A
5174288 Bardy et al. Dec 1992 A
5188602 Nichols Feb 1993 A
5191883 Lennox et al. Mar 1993 A
5213576 Abiuso et al. May 1993 A
5215103 Desai Jun 1993 A
5231996 Bardy et al. Aug 1993 A
5232444 Just et al. Aug 1993 A
5234456 Silvestrini Aug 1993 A
5254088 Lundquist et al. Oct 1993 A
5255678 Deslauriers et al. Oct 1993 A
5255679 Imran Oct 1993 A
5265604 Vince Nov 1993 A
5269758 Taheri Dec 1993 A
5281218 Imran Jan 1994 A
5292331 Boneau Mar 1994 A
5293869 Edwards et al. Mar 1994 A
5309910 Edwards et al. May 1994 A
5313943 Houser et al. May 1994 A
5324284 Imran Jun 1994 A
5343936 Beatenbough et al. Sep 1994 A
5345936 Pomeranz et al. Sep 1994 A
5366443 Eggers et al. Nov 1994 A
5368591 Lennox et al. Nov 1994 A
5370644 Langberg Dec 1994 A
5370679 Atlee, III Dec 1994 A
5374287 Rubin Dec 1994 A
5383917 Desai et al. Jan 1995 A
5393207 Maher et al. Feb 1995 A
5394880 Atlee, III Mar 1995 A
5396887 Imran Mar 1995 A
5400778 Jonson et al. Mar 1995 A
5400783 Pomeranz et al. Mar 1995 A
5411025 Webster, Jr. May 1995 A
5415166 Imran May 1995 A
5415656 Tihon et al. May 1995 A
5417687 Nardella et al. May 1995 A
5422362 Vincent et al. Jun 1995 A
5423744 Gencheff et al. Jun 1995 A
5423811 Imran et al. Jun 1995 A
5425023 Haraguchi et al. Jun 1995 A
5425703 Feiring Jun 1995 A
5425811 Mashita Jun 1995 A
5431696 Atlee, III Jul 1995 A
5433730 Alt Jul 1995 A
5437665 Munro Aug 1995 A
5443470 Stern et al. Aug 1995 A
5454782 Perkins Oct 1995 A
5456667 Ham et al. Oct 1995 A
5458596 Lax et al. Oct 1995 A
5465717 Imran et al. Nov 1995 A
5471982 Edwards et al. Dec 1995 A
5474530 Passafaro et al. Dec 1995 A
5478309 Sweezer et al. Dec 1995 A
5496271 Burton et al. Mar 1996 A
5496311 Abele et al. Mar 1996 A
5496312 Klicek Mar 1996 A
5500011 Desai Mar 1996 A
5505728 Ellman et al. Apr 1996 A
5505730 Edwards Apr 1996 A
5507791 Sit'ko Apr 1996 A
5509419 Edwards et al. Apr 1996 A
5522862 Testerman et al. Jun 1996 A
5531779 Dahl et al. Jul 1996 A
5540681 Strul et al. Jul 1996 A
5545161 Imran Aug 1996 A
5545193 Fleischman et al. Aug 1996 A
5547469 Rowland et al. Aug 1996 A
5549559 Eshel Aug 1996 A
5549655 Erickson Aug 1996 A
5549661 Kordis et al. Aug 1996 A
RE35330 Malone et al. Sep 1996 E
5558073 Pomeranz et al. Sep 1996 A
5562608 Sekins et al. Oct 1996 A
5571074 Buckman, Jr. et al. Nov 1996 A
5571088 Lennox et al. Nov 1996 A
5574059 Regunathan et al. Nov 1996 A
5578072 Barone et al. Nov 1996 A
5582609 Swanson et al. Dec 1996 A
5588432 Crowley Dec 1996 A
5588812 Taylor et al. Dec 1996 A
5595183 Swanson et al. Jan 1997 A
5598848 Swanson et al. Feb 1997 A
5599345 Edwards et al. Feb 1997 A
5601088 Swanson et al. Feb 1997 A
5605157 Panescu et al. Feb 1997 A
5607419 Amplatz et al. Mar 1997 A
5607462 Imran Mar 1997 A
5620438 Amplatz et al. Apr 1997 A
5623940 Daikuzono Apr 1997 A
5624439 Edwards et al. Apr 1997 A
5626618 Ward et al. May 1997 A
5630425 Panescu et al. May 1997 A
5630794 Lax et al. May 1997 A
5634471 Fairfax et al. Jun 1997 A
5641326 Adams Jun 1997 A
5647870 Kordis et al. Jul 1997 A
5660175 Dayal Aug 1997 A
5678535 DiMarco Oct 1997 A
5680860 Imran Oct 1997 A
5681280 Rusk et al. Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5687723 Avitall Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5693078 Desai et al. Dec 1997 A
5694934 Edelman Dec 1997 A
5695471 Wampler Dec 1997 A
5699799 Xu et al. Dec 1997 A
5702386 Stern et al. Dec 1997 A
5707218 Maher et al. Jan 1998 A
5707336 Rubin Jan 1998 A
5707352 Sekins et al. Jan 1998 A
5722401 Pietroski et al. Mar 1998 A
5722403 McGee et al. Mar 1998 A
5722416 Swanson et al. Mar 1998 A
5725525 Kordis Mar 1998 A
5727569 Benetti et al. Mar 1998 A
5728094 Edwards Mar 1998 A
5730128 Pomeranz et al. Mar 1998 A
5730704 Avitall Mar 1998 A
5730726 Klingenstein Mar 1998 A
5730741 Horzewski et al. Mar 1998 A
5735846 Panescu et al. Apr 1998 A
5740808 Panescu et al. Apr 1998 A
5741248 Stern et al. Apr 1998 A
5752518 McGee et al. May 1998 A
5755714 Murphy-Chutorian May 1998 A
5755753 Knowlton May 1998 A
5759158 Swanson Jun 1998 A
5765568 Sweezer, Jr. et al. Jun 1998 A
5769846 Edwards et al. Jun 1998 A
5772590 Webster, Jr. Jun 1998 A
5779669 Haissaguerre et al. Jul 1998 A
5779698 Clayman et al. Jul 1998 A
5782239 Webster, Jr. Jul 1998 A
5782797 Schweich, Jr. et al. Jul 1998 A
5782827 Gough et al. Jul 1998 A
5782848 Lennox Jul 1998 A
5782899 Imran Jul 1998 A
5792064 Panescu et al. Aug 1998 A
5795303 Swanson et al. Aug 1998 A
5800375 Sweezer et al. Sep 1998 A
5807306 Shapland et al. Sep 1998 A
5810757 Sweezer, Jr. et al. Sep 1998 A
5810807 Ganz et al. Sep 1998 A
5817028 Anderson Oct 1998 A
5817073 Krespi Oct 1998 A
5820554 Davis et al. Oct 1998 A
5823189 Kordis Oct 1998 A
5827277 Edwards Oct 1998 A
5833651 Donovan et al. Nov 1998 A
5836905 Lemelson et al. Nov 1998 A
5836947 Fleischman et al. Nov 1998 A
5837001 Mackey Nov 1998 A
5843075 Taylor Dec 1998 A
5843077 Edwards Dec 1998 A
5846238 Jackson et al. Dec 1998 A
5848969 Panescu et al. Dec 1998 A
5848972 Triedman et al. Dec 1998 A
5849026 Zhou et al. Dec 1998 A
5855577 Murphy-Chutorian et al. Jan 1999 A
5860974 Abele Jan 1999 A
5863291 Schaer Jan 1999 A
5865791 Whayne et al. Feb 1999 A
5868740 Leveen et al. Feb 1999 A
5871443 Edwards et al. Feb 1999 A
5871523 Fleischman et al. Feb 1999 A
5873852 Vigil et al. Feb 1999 A
5873865 Horzewski et al. Feb 1999 A
5876340 Tu et al. Mar 1999 A
5876399 Chia et al. Mar 1999 A
5881727 Edwards Mar 1999 A
5882346 Pomeranz et al. Mar 1999 A
5891135 Jackson et al. Apr 1999 A
5891136 McGee et al. Apr 1999 A
5891138 Tu et al. Apr 1999 A
5893847 Kordis Apr 1999 A
5897554 Chia et al. Apr 1999 A
5899882 Waksman et al. May 1999 A
5904651 Swanson et al. May 1999 A
5904711 Flom et al. May 1999 A
5906636 Casscells, III et al. May 1999 A
5908445 Whayne et al. Jun 1999 A
5908446 Imran Jun 1999 A
5908839 Levitt et al. Jun 1999 A
5911218 DiMarco Jun 1999 A
5916235 Guglielmi Jun 1999 A
5919147 Jain Jul 1999 A
5919172 Golba, Jr. Jul 1999 A
5924424 Stevens et al. Jul 1999 A
5928228 Kordis et al. Jul 1999 A
5931835 Mackey Aug 1999 A
5935079 Swanson et al. Aug 1999 A
5941869 Patterson et al. Aug 1999 A
5951494 Wang et al. Sep 1999 A
5951546 Lorentzen Sep 1999 A
5954661 Greenspon et al. Sep 1999 A
5954662 Swanson et al. Sep 1999 A
5954717 Behl et al. Sep 1999 A
5957961 Maguire et al. Sep 1999 A
5964753 Edwards Oct 1999 A
5964796 Imran Oct 1999 A
5971983 Lesh Oct 1999 A
5972026 Laufer et al. Oct 1999 A
5976175 Hirano et al. Nov 1999 A
5976709 Kageyama et al. Nov 1999 A
5979456 Magovern Nov 1999 A
5980563 Tu et al. Nov 1999 A
5984917 Fleischman et al. Nov 1999 A
5984971 Faccioli et al. Nov 1999 A
5991650 Swanson et al. Nov 1999 A
5992419 Sterzer et al. Nov 1999 A
5993462 Pomeranz et al. Nov 1999 A
5997534 Tu et al. Dec 1999 A
5999855 DiMarco Dec 1999 A
6001054 Regulla et al. Dec 1999 A
6003517 Sheffield et al. Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6006755 Edwards Dec 1999 A
6008211 Robinson et al. Dec 1999 A
6009877 Edwards Jan 2000 A
6010500 Sherman et al. Jan 2000 A
6014579 Pomeranz et al. Jan 2000 A
6016437 Tu et al. Jan 2000 A
6023638 Swanson Feb 2000 A
6024740 Lesh et al. Feb 2000 A
6029091 De La Rama et al. Feb 2000 A
6033397 Laufer et al. Mar 2000 A
6036687 Laufer et al. Mar 2000 A
6036689 Tu et al. Mar 2000 A
6039731 Taylor et al. Mar 2000 A
6045549 Smethers et al. Apr 2000 A
6045550 Simpson et al. Apr 2000 A
6050992 Nichols Apr 2000 A
6053172 Hovda et al. Apr 2000 A
6053909 Shadduck Apr 2000 A
6056744 Edwards May 2000 A
6056769 Epstein et al. May 2000 A
6063078 Wittkampf May 2000 A
6071280 Edwards et al. Jun 2000 A
6071281 Burnside et al. Jun 2000 A
6071282 Fleischman Jun 2000 A
6083255 Laufer et al. Jul 2000 A
6090104 Webster, Jr. Jul 2000 A
6092528 Edwards Jul 2000 A
6102886 Lundquist et al. Aug 2000 A
6106524 Eggers et al. Aug 2000 A
6123702 Swanson et al. Sep 2000 A
6123703 Tu et al. Sep 2000 A
6139527 Laufer et al. Oct 2000 A
6139571 Fuller et al. Oct 2000 A
6142993 Whayne et al. Nov 2000 A
6143013 Samson et al. Nov 2000 A
6149647 Tu et al. Nov 2000 A
6152143 Edwards Nov 2000 A
6152899 Farley et al. Nov 2000 A
6159194 Eggers et al. Dec 2000 A
6179833 Taylor Jan 2001 B1
6183468 Swanson et al. Feb 2001 B1
6198970 Freed et al. Mar 2001 B1
6200311 Danek et al. Mar 2001 B1
6200332 Del Giglio Mar 2001 B1
6200333 Laufer Mar 2001 B1
6210367 Carr Apr 2001 B1
6212433 Behl Apr 2001 B1
6214002 Fleischman et al. Apr 2001 B1
6216043 Swanson et al. Apr 2001 B1
6216044 Kordis Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6235024 Tu May 2001 B1
6241727 Tu et al. Jun 2001 B1
6245065 Panescu et al. Jun 2001 B1
6254598 Edwards et al. Jul 2001 B1
6258087 Edwards et al. Jul 2001 B1
6264653 Falwell Jul 2001 B1
6269813 Fitzgerald et al. Aug 2001 B1
6270476 Santoianni et al. Aug 2001 B1
6273907 Laufer Aug 2001 B1
6283988 Laufer et al. Sep 2001 B1
6283989 Laufer et al. Sep 2001 B1
6287304 Eggers et al. Sep 2001 B1
6296639 Truckai et al. Oct 2001 B1
6299633 Laufer Oct 2001 B1
6322559 Daulton et al. Nov 2001 B1
6322584 Ingle et al. Nov 2001 B2
6338727 Noda et al. Jan 2002 B1
6338836 Kuth et al. Jan 2002 B1
6346104 Daly et al. Feb 2002 B2
6355031 Edwards et al. Mar 2002 B1
6379352 Reynolds et al. Apr 2002 B1
6409723 Edwards Jun 2002 B1
6411852 Danek et al. Jun 2002 B1
6416511 Lesh et al. Jul 2002 B1
6416740 Unger Jul 2002 B1
6423105 Iijima et al. Jul 2002 B1
6425895 Swanson et al. Jul 2002 B1
6440129 Simpson Aug 2002 B1
6442435 King et al. Aug 2002 B2
6458121 Rosenstock et al. Oct 2002 B1
6460545 Kordis Oct 2002 B2
6488673 Laufer et al. Dec 2002 B1
6488679 Swanson et al. Dec 2002 B1
6493589 Medhkour et al. Dec 2002 B1
6494880 Swanson et al. Dec 2002 B1
6496738 Carr Dec 2002 B2
6514246 Swanson et al. Feb 2003 B1
6526320 Mitchell Feb 2003 B2
6529756 Phan et al. Mar 2003 B1
6544226 Gaiser et al. Apr 2003 B1
6544262 Fleischman Apr 2003 B2
6547788 Maguire et al. Apr 2003 B1
6558378 Sherman et al. May 2003 B2
6572612 Stewart et al. Jun 2003 B2
6575623 Werneth Jun 2003 B2
6575969 Rittman, III et al. Jun 2003 B1
6582427 Goble et al. Jun 2003 B1
6582430 Hall Jun 2003 B2
6589235 Wong et al. Jul 2003 B2
6610054 Edwards et al. Aug 2003 B1
6620159 Hegde Sep 2003 B2
6626903 McGuckin, Jr. et al. Sep 2003 B2
6634363 Danek et al. Oct 2003 B1
6635056 Kadhiresan et al. Oct 2003 B2
6638273 Farley et al. Oct 2003 B1
6640120 Swanson et al. Oct 2003 B1
6645200 Koblish et al. Nov 2003 B1
6652548 Evans et al. Nov 2003 B2
6669693 Friedman Dec 2003 B2
6673068 Berube Jan 2004 B1
6692492 Simpson et al. Feb 2004 B2
6699243 West et al. Mar 2004 B2
6714822 King et al. Mar 2004 B2
6723091 Goble et al. Apr 2004 B2
6743197 Edwards Jun 2004 B1
6749604 Eggers et al. Jun 2004 B1
6749606 Keast et al. Jun 2004 B2
6767347 Sharkey et al. Jul 2004 B2
6770070 Balbierz Aug 2004 B1
6802843 Truckai et al. Oct 2004 B2
6805131 Kordis Oct 2004 B2
6837888 Ciarrocca et al. Jan 2005 B2
6840243 Deem et al. Jan 2005 B2
6849073 Hoey et al. Feb 2005 B2
6852091 Edwards et al. Feb 2005 B2
6852110 Roy et al. Feb 2005 B2
6866662 Fuimaono et al. Mar 2005 B2
6881213 Ryan et al. Apr 2005 B2
6893436 Woodard et al. May 2005 B2
6893439 Fleischman May 2005 B2
6895267 Panescu et al. May 2005 B2
6904303 Phan et al. Jun 2005 B2
6917834 Koblish et al. Jul 2005 B2
6939346 Kannenberg et al. Sep 2005 B2
6954977 Maguire et al. Oct 2005 B2
7027869 Danek et al. Apr 2006 B2
7043307 Zelickson et al. May 2006 B1
7104987 Biggs et al. Sep 2006 B2
7104990 Jenkins et al. Sep 2006 B2
7118568 Hassett et al. Oct 2006 B2
7122033 Wood Oct 2006 B2
7131445 Amoah Nov 2006 B2
7186251 Malecki et al. Mar 2007 B2
7198635 Danek et al. Apr 2007 B2
7200445 Dalbec et al. Apr 2007 B1
7241295 Maguire Jul 2007 B2
7255693 Johnston et al. Aug 2007 B1
7264002 Danek et al. Sep 2007 B2
7266414 Cornelius et al. Sep 2007 B2
7273055 Danek et al. Sep 2007 B2
7425212 Danek et al. Sep 2008 B1
7542802 Biggs et al. Jun 2009 B2
7556624 Laufer et al. Jul 2009 B2
7740017 Danek et al. Jun 2010 B2
20030050631 Mody et al. Mar 2003 A1
20030065371 Satake Apr 2003 A1
20030069570 Witzel et al. Apr 2003 A1
20030187430 Vorisek Oct 2003 A1
20030236455 Swanson et al. Dec 2003 A1
20040010289 Biggs et al. Jan 2004 A1
20040153056 Muller et al. Aug 2004 A1
20040249401 Rabiner et al. Dec 2004 A1
20050010270 Laufer Jan 2005 A1
20050096644 Hall et al. May 2005 A1
20050171396 Pankratov et al. Aug 2005 A1
20050193279 Daners Sep 2005 A1
20050203503 Edwards et al. Sep 2005 A1
20050240176 Oral et al. Oct 2005 A1
20050251128 Amoah Nov 2005 A1
20060062808 Laufer et al. Mar 2006 A1
20060079887 Buysse et al. Apr 2006 A1
20060089637 Werneth et al. Apr 2006 A1
20060135953 Kania et al. Jun 2006 A1
20060137698 Danek et al. Jun 2006 A1
20060247617 Danek et al. Nov 2006 A1
20060247618 Kaplan et al. Nov 2006 A1
20060247619 Kaplan et al. Nov 2006 A1
20060247726 Biggs et al. Nov 2006 A1
20060247746 Danek et al. Nov 2006 A1
20060254600 Danek et al. Nov 2006 A1
20060278243 Danek et al. Dec 2006 A1
20060278244 Danek et al. Dec 2006 A1
20060282071 Utley et al. Dec 2006 A1
20070074719 Danek et al. Apr 2007 A1
20070083194 Kunis et al. Apr 2007 A1
20070083197 Danek et al. Apr 2007 A1
20070100390 Danaek et al. May 2007 A1
20070102011 Danek et al. May 2007 A1
20070106292 Kaplan et al. May 2007 A1
20070106296 Laufer et al. May 2007 A1
20070106348 Laufer May 2007 A1
20070118184 Danek et al. May 2007 A1
20070118190 Danek May 2007 A1
20070123958 Laufer May 2007 A1
20070123961 Danek et al. May 2007 A1
20070129720 Demarais et al. Jun 2007 A1
20080004596 Yun et al. Jan 2008 A1
20080097424 Wizeman et al. Apr 2008 A1
20080255642 Zarins et al. Oct 2008 A1
20090018538 Webster et al. Jan 2009 A1
20090030477 Jarrard Jan 2009 A1
20090043301 Jarrard et al. Feb 2009 A1
20090069797 Danek et al. Mar 2009 A1
20090112203 Danek et al. Apr 2009 A1
20090143705 Danek et al. Jun 2009 A1
20090143776 Danek et al. Jun 2009 A1
20090192505 Askew et al. Jul 2009 A1
20090192508 Laufer et al. Jul 2009 A1
20090306644 Mayse et al. Dec 2009 A1
Foreign Referenced Citations (49)
Number Date Country
19529634 Feb 1997 DE
189329 Jun 1987 EP
286145 Oct 1988 EP
280225 Mar 1989 EP
286145 Oct 1990 EP
282225 Jun 1992 EP
0 908 713 Apr 1999 EP
908150 Apr 1999 EP
768091 Jul 2003 EP
1297795 Aug 2005 EP
2659240 Jul 1997 FR
2233293 Jan 1991 GB
2233293 Feb 1994 GB
59167707 Sep 1984 JP
7289557 Nov 1995 JP
9047518 Feb 1997 JP
9243837 Sep 1997 JP
10026709 Jan 1998 JP
2053814 Feb 1996 RU
2091054 Sep 1997 RU
545358 Feb 1977 SU
WO-8911311 Nov 1989 WO
WO-9502370 Jan 1995 WO
WO-9510322 Apr 1995 WO
WO-9604860 Feb 1996 WO
WO-9610961 Apr 1996 WO
WO-9732532 Sep 1997 WO
WO-9733715 Sep 1997 WO
WO-9737715 Oct 1997 WO
WO-9740751 Nov 1997 WO
WO-9844854 Oct 1998 WO
WO-9852480 Nov 1998 WO
WO-9856234 Dec 1998 WO
WO-9856324 Dec 1998 WO
WO-9858681 Dec 1998 WO
WO 9903413 Jan 1999 WO
WO-9913779 Mar 1999 WO
WO-9932040 Jul 1999 WO
WO-9934741 Jul 1999 WO
WO-9944506 Sep 1999 WO
WO-9945855 Sep 1999 WO
WO-9964109 Dec 1999 WO
WO-0051510 Sep 2000 WO
WO-0062699 Oct 2000 WO
WO-0103642 Jan 2001 WO
WO-0232333 Apr 2002 WO
WO-0232334 Apr 2002 WO
WO-2009082433 Jul 2009 WO
WO-2009137819 Nov 2009 WO
Related Publications (1)
Number Date Country
20060247727 A1 Nov 2006 US
Divisions (1)
Number Date Country
Parent 10414411 Apr 2003 US
Child 11458084 US
Continuations (1)
Number Date Country
Parent PCT/US01/32321 Oct 2001 US
Child 10414411 US
Continuation in Parts (1)
Number Date Country
Parent PCT/US00/28745 Oct 2000 US
Child PCT/US01/32321 US